315 related articles for article (PubMed ID: 29663017)
1. Cyclic nucleotide phosphodiesterases: potential therapeutic targets for alcohol use disorder.
Wen RT; Zhang FF; Zhang HT
Psychopharmacology (Berl); 2018 Jun; 235(6):1793-1805. PubMed ID: 29663017
[TBL] [Abstract][Full Text] [Related]
2. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.
Kokkonen K; Kass DA
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():455-479. PubMed ID: 27732797
[TBL] [Abstract][Full Text] [Related]
3. Cyclic Nucleotide Phosphodiesterases in Alcohol Use Disorders: Involving Gut Microbiota.
Hou X; Rong C; Zhang Q; Song S; Cong Y; Zhang HT
Int J Neuropsychopharmacol; 2023 Jan; 26(1):70-79. PubMed ID: 36087271
[TBL] [Abstract][Full Text] [Related]
4. Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
Guo L; Luo L; Ju R; Chen C; Zhu L; Li J; Yu X; Ye C; Zhang D
Eur J Pharmacol; 2015 Jan; 746():14-21. PubMed ID: 25446933
[TBL] [Abstract][Full Text] [Related]
5. Modulation of Compartmentalised Cyclic Nucleotide Signalling via Local Inhibition of Phosphodiesterase Activity.
Brescia M; Zaccolo M
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27706091
[TBL] [Abstract][Full Text] [Related]
6. ABCD of the phosphodiesterase family: interaction and differential activity in COPD.
Halpin DM
Int J Chron Obstruct Pulmon Dis; 2008; 3(4):543-61. PubMed ID: 19281073
[TBL] [Abstract][Full Text] [Related]
7. Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.
Ahmad F; Murata T; Shimizu K; Degerman E; Maurice D; Manganiello V
Oral Dis; 2015 Jan; 21(1):e25-50. PubMed ID: 25056711
[TBL] [Abstract][Full Text] [Related]
8. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
9. Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro.
Truss MC; Uckert S; Stief CG; Schulz-Knappe P; Hess R; Forssmann WG; Jonas U
Urology; 1995 May; 45(5):893-901. PubMed ID: 7747383
[TBL] [Abstract][Full Text] [Related]
10. The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion.
Han P; Werber J; Surana M; Fleischer N; Michaeli T
J Biol Chem; 1999 Aug; 274(32):22337-44. PubMed ID: 10428803
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty.
Zhao H; Quilley J; Montrose DC; Rajagopalan S; Guan Q; Smith CJ
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2973-81. PubMed ID: 17293498
[TBL] [Abstract][Full Text] [Related]
12. The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure.
Nadur NF; de Azevedo LL; Caruso L; Graebin CS; Lacerda RB; Kümmerle AE
Eur J Med Chem; 2021 Feb; 212():113123. PubMed ID: 33412421
[TBL] [Abstract][Full Text] [Related]
13. Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells.
Lugnier C; Schini VB
Biochem Pharmacol; 1990 Jan; 39(1):75-84. PubMed ID: 2153383
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of a phosphodiesterase III in the lysis-sensitive target-induced elevation of cyclic AMP (cAMP) in human natural killer cells.
Whalen MM; Crews JD
Biochem Pharmacol; 2000 Aug; 60(4):499-506. PubMed ID: 10874124
[TBL] [Abstract][Full Text] [Related]
15. Cyclic nucleotide phosphodiesterases: critical modulators of endocrine, metabolic, and cardiovascular function and appealing therapeutic targets.
Manganiello V
Curr Opin Pharmacol; 2011 Dec; 11(6):646-8. PubMed ID: 22079477
[No Abstract] [Full Text] [Related]
16. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis.
Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
Cell Signal; 2001 Mar; 13(3):159-67. PubMed ID: 11282454
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase regulation of alcohol drinking in rodents.
Logrip ML
Alcohol; 2015 Dec; 49(8):795-802. PubMed ID: 26095589
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries.
Birk S; Edvinsson L; Olesen J; Kruuse C
Eur J Pharmacol; 2004 Apr; 489(1-2):93-100. PubMed ID: 15063160
[TBL] [Abstract][Full Text] [Related]
19. Interaction of cyclic GMP and cyclic AMP during neutrophil migration: involvement of phosphodiesterase type III.
VanUffelen BE; de Koster BM; Elferink JG
Biochem Pharmacol; 1998 Oct; 56(8):1061-3. PubMed ID: 9776319
[TBL] [Abstract][Full Text] [Related]
20. cGMP stimulates renin secretion in vivo by inhibiting phosphodiesterase-3.
Beierwaltes WH
Am J Physiol Renal Physiol; 2006 Jun; 290(6):F1376-81. PubMed ID: 16449359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]